Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: Timing and specimen types

Sherene Loi, W. Fraser Symmans, John M S Bartlett, Debora Fumagalli, Laura Van t Veer, John F. Forbes, Philippe Bedard, Carsten Denkert, JoAnne Zujewski, Giuseppe Viale, Lajos Pusztai, Laura J. Esserman, Brian R. Leyland-Jones

Research output: Contribution to journalArticlepeer-review


In this Personal View, we outline proposals for uniform collection of biospecimens obtained in neoadjuvant breast cancer trials undertaken by the Breast International Group (BIG) and the National Cancer Institute-sponsored North American Breast Cancer Group (NABCG). These proposals aim to standardise collection of high-quality specimens, with respect to both type and timing, to enhance and allow integration of results obtained from neoadjuvant trials done by several groups. They should be considered in parallel with recommendations for tissue-specimen collection and handling previously developed by BIG and NABCG. We propose that tumour tissue (formalin-fixed, paraffin-embedded and samples dedicated for molecular studies) should be taken at baseline, 1-3 weeks after the start of treatment, and at definitive surgery, with clear prioritisation in the study protocol of number, order, and preservation of samples to be gathered. This step should be accompanied by blood collection (plasma, serum, and whole blood) whenever possible. We advocate strongly a move towards one diagnostic and research biopsy procedure in all women with breast cancers potentially suitable for neoadjuvant treatment. If possible, patients should be referred at the outset to specialised centres to give them the opportunity to participate in neoadjuvant clinical trials, thereby avoiding several biopsy procedures.

Original languageEnglish
Pages (from-to)1162-1168
Number of pages7
JournalThe Lancet Oncology
Issue number12
Publication statusPublished - Nov 2011

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: Timing and specimen types'. Together they form a unique fingerprint.

Cite this